Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Default user image.

Katarina Sjögreen Gleisner

Professor

Default user image.

A PBPK model for PRRT with [177Lu]Lu-DOTA-TATE : Comparison of model implementations in SAAM II and MATLAB/SimBiology

Författare

  • Valentina Vasić
  • Johan Gustafsson
  • Elham Yousefzadeh Nowshahr
  • Anna Stenvall
  • Ambros J. Beer
  • Katarina Sjögreen Gleisner
  • Gerhard Glatting

Summary, in English

Physiologically based pharmacokinetic (PBPK) models offer the ability to simulate and predict the biodistribution of radiopharmaceuticals and have the potential to enable individualised treatment planning in molecular radiotherapy. The objective of this study was to develop and implement a whole-body compartmental PBPK model for peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-DOTA-TATE in SimBiology to allow for more complex analyses. The correctness of the model implementation was ensured by comparing its outputs, such as the time-integrated activity (TIA), with those of a PBPK model implemented in SAAM II software. Methods: A combined PBPK model for [68Ga]Ga-DOTA-TATE and [177Lu]Lu-DOTA-TATE was developed and implemented in both SAAM II and SimBiology. A retrospective analysis of 12 patients with metastatic neuroendocrine tumours (NETs) was conducted. First, time-activity curves (TACs) and TIAs from the two software were calculated and compared for identical parameter values. Second, pharmacokinetic parameters were fitted to activity concentrations, analysed and compared. Results: The PBPK model implemented in SimBiology produced TIA results comparable to those generated by the model implemented in SAAM II, with a relative deviation of less than 0.5% when using the same input parameters. The relative deviation of the fitted TIAs was less than 5% when model parameter values were fitted to the measured activity concentrations. Conclusion: The proposed PBPK model implemented in SimBiology can be used for dosimetry in radioligand therapy and TIA prediction. Its outputs are similar to those generated by the PBPK model implemented in SAAM II, confirming the correctness of the model implementation in SimBiology.

Avdelning/ar

  • Medicinsk strålningsfysik, Lund
  • Nuclear Medicine Physics
  • Forskningsgruppen för Systemisk strålterapi

Publiceringsår

2024

Språk

Engelska

Publikation/Tidskrift/Serie

Physica Medica

Volym

119

Dokumenttyp

Artikel i tidskrift

Förlag

ISTITUTI EDITORIALI E POLGRAFICI INTERNAZIONALI

Ämne

  • Radiology, Nuclear Medicine and Medical Imaging

Nyckelord

  • Comparison of model implementations
  • Peptide receptor radionuclide therapy
  • Physiologically based pharmacokinetic model

Status

Published

Forskningsgrupp

  • Nuclear Medicine Physics
  • Systemic Radiation Therapy Group

ISBN/ISSN/Övrigt

  • ISSN: 1120-1797